Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NRAS Q61H Alpelisib + Binimetinib rhabdomyosarcoma sensitive detail...
NRAS Q61H Rigosertib rhabdomyosarcoma not predictive detail...
HRAS Q61K Rigosertib rhabdomyosarcoma not predictive detail...
HRAS Q61K Trametinib rhabdomyosarcoma no benefit detail...
NRAS Q61H Trametinib rhabdomyosarcoma no benefit detail...
HRAS Q61K LY3009120 + Trametinib rhabdomyosarcoma sensitive detail...
NRAS Q61H LY3009120 + Trametinib rhabdomyosarcoma sensitive detail...
NRAS Q61L LY3009120 + Trametinib rhabdomyosarcoma sensitive detail...
HRAS Q61K LY3214996 + Trametinib rhabdomyosarcoma sensitive detail...
NRAS Q61H LY3214996 + Trametinib rhabdomyosarcoma sensitive detail...
NRAS Q61L LY3214996 + Trametinib rhabdomyosarcoma sensitive detail...
HRAS Q61K LY3009120 + LY3214996 rhabdomyosarcoma sensitive detail...
NRAS Q61H LY3009120 + LY3214996 rhabdomyosarcoma sensitive detail...
NRAS Q61L LY3009120 + LY3214996 rhabdomyosarcoma sensitive detail...
HRAS Q61K Ganitumab + Trametinib rhabdomyosarcoma sensitive detail...
NRAS Q61H Ganitumab + Trametinib rhabdomyosarcoma predicted - sensitive detail...
HRAS Q61K PTEN dec exp Trametinib rhabdomyosarcoma resistant detail...
HRAS Q61K PTEN dec exp Ganitumab + Trametinib rhabdomyosarcoma sensitive detail...
NRAS Q61H PTEN over exp Ganitumab + Trametinib rhabdomyosarcoma sensitive detail...
HRAS G13R Ganitumab + Trametinib rhabdomyosarcoma sensitive detail...
NRAS G13D Ganitumab + Trametinib rhabdomyosarcoma sensitive detail...
NRAS G13R PIK3CA H1047R Ganitumab + Trametinib rhabdomyosarcoma resistant detail...
BRAF V600E CDKN2A R80* Dabrafenib + Palbociclib + Trametinib rhabdomyosarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed USA 0
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01446809 Phase I Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Completed USA 0
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed USA 0
NCT01661400 Phase I Cyclophosphamide Thalidomide Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors Completed USA 0
NCT01871766 Phase II Bevacizumab + Cyclophosphamide + Sorafenib Dactinomycin + Vincristine Sulfate Cyclophosphamide + Dactinomycin + Vincristine Sulfate Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery Active, not recruiting USA 0
NCT02013336 Phase I Cyclophosphamide + Liposomal irinotecan Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Unknown status USA 0
NCT02095132 Phase Ib/II Adavosertib + Irinotecan Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed USA | CAN 0
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Completed USA 0
NCT02303028 Phase Ib/II Pazopanib + Topotecan Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours Completed CAN 0
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Completed USA | CAN 0
NCT02372006 Phase Ib/II Afatinib Trial of Afatinib in Pediatric Tumours Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 2
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting USA 0
NCT02446431 Phase I Cyclophosphamide Bevacizumab Temsirolimus Valproic acid Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Recruiting USA 0
NCT02567435 Phase III Cyclophosphamide + Dactinomycin + Vincristine Sulfate Temsirolimus Irinotecan Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Active, not recruiting USA | NZL | CAN | AUS 1
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting USA 0
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Completed USA 0
NCT02789228 Phase I MultiTAA-specific T cells Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) Active, not recruiting USA 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02890758 Phase I Nogapendekin alfa inbakicept Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed USA 0
NCT03139331 Phase I Irinotecan + Pazopanib + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Completed USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213678 Phase II LY3023414 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Unknown status USA 0
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03245151 Phase Ib/II Everolimus + Lenvatinib Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Completed USA | CAN 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU 2
NCT03441360 Phase II Eribulin Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Completed USA 0
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Terminated USA 0
NCT03585465 Phase Ib/II Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors Suspended FRA | BEL 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03709680 Phase I Irinotecan + Palbociclib + Temozolomide Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 12
NCT04095221 Phase Ib/II Irinotecan + Prexasertib + Temozolomide A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Active, not recruiting USA 0
NCT04216953 Phase Ib/II Atezolizumab + Cobimetinib MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) Recruiting FRA 0
NCT04299113 Phase I Mocetinostat + Vinorelbine Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma Recruiting USA 0
NCT04469530 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) Recruiting USA 0
NCT04544995 Phase I Dostarlimab-gxly + Niraparib Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors Suspended GBR | FRA | ESP | DEU 2
NCT04625907 Phase Ib/II Irinotecan + Temozolomide + Vincristine Sulfate Dactinomycin + Ifosfamide + Vincristine Sulfate Irinotecan + Regorafenib + Vincristine Sulfate Dactinomycin + Ifosfamide + Irinotecan + Vincristine Sulfate Dactinomycin + Doxorubicin + Ifosfamide + Vincristine Sulfate Cyclophosphamide + Vinorelbine FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS) Recruiting NZL | NLD | ITA | GBR | FRA | ESP | BEL | AUT | AUS 10
NCT04796012 Phase Ib/II Atezolizumab + Irinotecan + Temozolomide + Vincristine Sulfate VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors Recruiting USA 0
NCT04906876 Phase II Docetaxel + Elraglusib + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT05064306 Expanded access Omburtamab I-131 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults Available USA 0
NCT05093322 Phase Ib/II Gemcitabine + Surufatinib A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT05116800 Phase II Docetaxel + Elraglusib + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05131386 Phase II Dexamethasone + Trabectedin Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) Recruiting ESP 0
NCT05135975 Phase II Cabozantinib A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Recruiting USA 0
NCT05253131 Phase Ib/II AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas Not yet recruiting USA 0
NCT05302921 Phase II Ipilimumab + Nivolumab Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Active, not recruiting USA 0
NCT05429502 Phase Ib/II Ribociclib + Temozolomide + Topotecan Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | AUS 1
NCT06094101 Phase Ib/II Peptide vaccine IPX Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (PerVision) Recruiting DEU 0